

Supplementary Table 5: Clinical, pathological characteristics and treatments of patients and tumors of the two genomic sub-groups of IMPC.

	Sawtooth / 8/16 / [n (%)]	Firestorm/Amplifier/ [n (%)]	<i>p-val</i>
Number of patients	16	19	
Median FU, yrs [range]	5.9 [0.6 - 10.2]	7.5 [1.1 - 10.7]	
Median age, yrs [range]	61 [39 - 84]	62 [34 - 83]	
< 50	1 (6)	6 (32)	ns
> 50	15 (94)	13 (68)	
Tumor size, cm			
< 2	12 (75)	12 (63)	ns
2 to 5	3 (19)	6 (32)	ns
> 5	1 (6)	1 (5)	ns
Grade			
I	2 (13)	0 (0)	ns
II	7 (44)	11 (58)	ns
III	7 (44)	7 (37)	ns
Not specified	0 (0)	1 (5)	
Nodal status			
Positive	9 (56)	11 (58)	ns
Negative	6 (38)	7 (37)	
Not specified	1 (6)	1 (5)	
Lyhovoascular invasion			
Positive	14 (88)	15 (79)	ns
Negative	2 (13)	3 (16)	
Not specified	0 (0)	1 (5)	
Conservative surgery	11 (69)	10 (53)	ns
Adjuvant therapies			
Anti-HER2 therapy	1 (100)	4 (44)	ns
Chemotherapy	6 (38)	12 (63)	ns
Hormone treatment	15 (94)	16 (84)	ns
ER			
Positive	16 (100)	19 (100)	ns
Negative	0 (0)	0 (0)	
ERBB2			
Positive	1 (6)	9 (47)	7.3×10^{-3}
Negative	13 (81)	9 (47)	
Not specified	2 (13)	1 (5)	